Evidence map›Paper›PMID 36144938›Full record

ArticleNanomaterials (Basel, Switzerland)2022

Multifaceted Elevation of ROS Generation for Effective Cancer Suppression.

Huizhe Wang, Mengyuan Cui, Yanqi Xu, Tianguang Liu, Yueqing Gu, Peng Wang, Hui Tang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Huizhe WangStem Cell Clinical Research Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Mengyuan CuiDepartment of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China.
Yanqi XuDepartment of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China.
Tianguang LiuDepartment of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China.
Yueqing GuDepartment of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China.
Peng WangDepartment of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China.ORCID 0000-0003-2359-908X
Hui TangStem Cell Clinical Research Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.ORCID 0000-0002-7274-1487
China Pharmaceutical University · CNShandong Provincial Hospital · CN

Funding

National Natural Science Foundation of China 82071979
6 · The paper itself

Abstract

The in situ lactate oxidase (LOx) catalysis is highly efficient in reducing oxygen to H

Indexed as

cancerCDTlactate oxidasePDTROS

Identifiers

PMID36144938
PMCPMC9502709
OpenAlexW4296012283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.